Loading...

2,281 posters, 63 videos, 56 audios, 43 topics, 18 sessions, 6,174 authors, 2,323 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

RCOG World Congress 2025

June 23 - 25, 2025 | ExCeL London, UK

EP.1375

Episiotomy in the USA: have we got it right?

Part of Topic

Intrapartum care

Episiotomy: Have we got it right?

Background: A recent randomized controlled trial (Bergendahl et al, BMJ 2024) reported a 50% reduction in obstetric anal sphincter injury (OASI) in nulliparous patients undergoing vacuum delivery who were assigned to lateral episiotomy versus no episiotomy.

Objective: To evaluate OASI in singleton nulliparous vacuum deliveries at >= 34 weeks’ gestation in a US population.

Materials and Methods: 

Study design: Retrospective observational study.

Population: Singleton nulliparous vacuum deliveries at >= 34 weeks’ gestation at 17 US hospitals (2022-2023) participating in a perinatal quality improvement program (OB COAP)

Intervention: Midline (M)  or mediolateral  (ML) episiotomy versus no episiotomy (N).

Primary outcome: Incidence of 3rd or 4th degree laceration (Obstetrical anal sphincter injury or OASI). 

Secondary outcome: blood loss.

Statistical analysis: Unadjusted odds ratios (OR) for OASI were calculated for each ML and M group compared to the N group. Adjusted ORs controlled for diabetes (gestational and pre-pregnancy)  and birthweight. The Kruskal-Wallis test was used to compare blood loss.

 Results: 

915 vacuum deliveries were included. 148 (16.1%) had an episiotomy: 79 (53.4%) were midline and 69 (46.6%) were mediolateral.

Conclusions: 
In nulliparous patients undergoing vacuum delivery, midline episiotomy was associated with increased risk of OASI compared to mediolateral episiotomy or to no episiotomy.
Given the evidence from a new European randomized controlled trial, more research is needed to determine whether mediolateral episiotomy in nulliparous vacuum deliveries might reduce OASI in a US population.

 

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.